Cardiovascular safety profile of romosozumab: A pharmacovigilance analysis of the US Food and Drug Administration adverse event reporting system (FAERS)

被引：0
|
作者：
Kvist, Annika [1 ]
Faruque, Junaid A. Y. [2 ]
Burden, Andrea M. [1 ]
机构：
[1] Swiss Fed Inst Technol, Inst Pharmaceut Sci, Dept Chem & Appl Biosci, Zurich, Switzerland
[2] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2021年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
引用
收藏
页码：159 / 160
页数：2
相关论文
共 50 条
  • [1] Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Kvist, Annika Vestergaard
    Faruque, Junaid
    Vallejo-Yague, Enriqueta
    Weiler, Stefan
    Winter, Elizabeth M.
    Burden, Andrea M.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (08)
  • [2] Real-World Safety Profile of Luspatercept: A Pharmacovigilance Analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS)
    Batra, Akshee
    Singh, Rohit
    Brunstein, Claudio
    Alejos, David
    Adrianzen-Herrera, Diego
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S369 - S369
  • [3] US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)
    Thomas J. Moore
    Richard L. Morrow
    Colin R. Dormuth
    Barbara Mintzes
    [J]. Pharmaceutical Medicine, 2020, 34 : 135 - 140
  • [4] US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS)
    Moore, Thomas J.
    Morrow, Richard L.
    Dormuth, Colin R.
    Mintzes, Barbara
    [J]. PHARMACEUTICAL MEDICINE, 2020, 34 (02) : 135 - 140
  • [5] Sodium-glucose cotransporter-2 inhibitors and cardiovascular safety profile: a pharmacovigilance analysis of the US food and drug administration adverse event reporting system
    Zhang, Lei
    Pan, Chen
    Yang, Xinyu
    Jiang, Dechun
    Cao, Mingnan
    [J]. EXPERT OPINION ON DRUG SAFETY, 2023,
  • [6] Analysis of Information on Drug Adverse Reactions Using US Food and Drug Administration Adverse Event Reporting System (FAERS)
    Nango, Daisuke
    Sekizuka, Tuyoshi
    Goto, Makoto
    Echizen, Hirotoshi
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2022, 142 (04): : 341 - 344
  • [7] A pharmacovigilance study of adverse events associated with polymyxins based on the US Food and Drug Administration Adverse Event Reporting System (FAERS) database
    Wu, Tingxi
    Shi, Yanfeng
    Xu, Chang
    Zhu, Bin
    Li, Dandan
    Li, Zhe
    Zhao, Zhigang
    Zhang, Yang
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024,
  • [8] Cardiovascular and Cerebrovascular Safety of Ranibizumab, Bevacizumab, and Aflibercept in Ocular Diseases: An Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database
    Zeng, Yanbin
    Guo, Xiaohui
    Xiao, Fengjiao
    Zhang, Haixia
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (08): : 909 - 917
  • [9] Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
    Meilian Zhang
    Wenhuo Xie
    Jianbin Li
    Jiaping Zheng
    Yu Zhou
    [J]. Archives of Women's Mental Health, 2024, 27 : 35 - 44
  • [10] Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
    Zhang, Meilian
    Xie, Wenhuo
    Li, Jianbin
    Zheng, Jiaping
    Zhou, Yu
    [J]. ARCHIVES OF WOMENS MENTAL HEALTH, 2023, 27 (1) : 35 - 44
12345